Contract service agreement for development of ST-669Contract Service Agreement • February 13th, 2022
Contract Type FiledFebruary 13th, 2022Awarded a $2.8 million contract with options for up to $9.9 million from the Department of Defense's Transformational Medical Technologies Initiative (TMTI) through the Defense Threat Reduction Agency (DTRA) to support the preclinical development and Investigation New Drug (IND) filing of ST-669, a broad spectrum antiviral that has demonstrated in vitro antiviral activity against several different viral families.
Contract service agreement for development of ST-669Contract Service Agreement • September 27th, 2021
Contract Type FiledSeptember 27th, 2021Awarded a $2.8 million contract with options for up to $9.9 million from the Department of Defense's Transformational Medical Technologies Initiative (TMTI) through the Defense Threat Reduction Agency (DTRA) to support the preclinical development and Investigation New Drug (IND) filing of ST-669, a broad spectrum antiviral that has demonstrated in vitro antiviral activity against several different viral families.